VEGFA and neoplasm: Exposure to VEGF-targeting medication results in tumor hypoxia, causing tumor cells to release HIF1α that stimulates the epithelial cells to acquire mesenchymal characteristics, also known as epithelial-mesenchymal Transition (EMT).